Evotec

Are you working on multi-omics research? To gain insight from omics data, it is critical to combine information from multiple sources. Let PanHunter® help you! With true multi-omics support, PanHunter brings together all necessary data and information sources. You can analyse and interpret data from any omics platform and protocol, across species borders, next to each other, or together. Contact us now to deep dive into your multi-omics data with PanHunter: https://hubs.ly/Q03hQVPX0 #researchneverstops #medicinesthatmatter #drugdiscovery #panhunter #bioinformatics #omics #dataanalysis #datascience #transcriptomics #proteomics #singlecell #spatial

Evotec SE today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process. Read the full press release to learn more - https://hubs.ly/Q03hN2n30

𝘈𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘪𝘯𝘨 𝘴𝘮𝘢𝘭𝘭 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦 𝘙𝘕𝘈-𝘵𝘢𝘳𝘨𝘦𝘵𝘦𝘥 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘸𝘪𝘵𝘩 𝘙𝘕𝘈 𝘈𝘵𝘭𝘢𝘴! At Evotec, we’ve developed 𝗥𝗡𝗔 𝗔𝘁𝗹𝗮𝘀 — a proprietary tool designed to: • Prioritize RNA targets and regions of interest • Identify druggable RNA pockets by small molecule • Suggest chemical probes • Flag potential off-targets Built on a curated database of 2D structural RNA motifs derived from the PDB, 𝗥𝗡𝗔 𝗔𝘁𝗹𝗮𝘀 enables rapid identification of known or similar motifs in new RNA targets—bringing valuable insights to each new project. Smarter decisions. Faster progress. Want to learn more? Reach out at steffen.grimm@evotec.com #RNA #RNAAtlas #DrugDiscovery #StructuralBiology #Evotec #Biotech #CRO #Innovation #RNAResearch #SmallMolecules #TogetherForMedicinesThatMatter

We are excited that data from Evotec's groundbreaking collaboration with Sernova Biotherapeutics was spotlighted today at the Cell & Gene Meeting on the Med conference in Rome! Bernd Muehlenweg, SVP, Head of Global Business Development Cell Therapy, Evotec and Non-Executive Director, Sernova presented within the panel discussion entitled "Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions". Evotec's and Sernova's collaborative approach comprises a novel strategy for a functional cure for type 1 diabetes combining Sernova's Cell Pouch Bio-hybrid Organ and Evotec's iPSC-derived islet-like clusters. Find out more about the panel and Evotec's presence at the conference, and reach out to us if you would like to meet https://hubs.ly/Q03hC8PH0 #celltherapy #CGMed25 #iPSC

Now available to watch on-demand! 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗟𝗡𝗔 𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗶𝗻 𝗮𝗻𝘁𝗶𝘀𝗲𝗻𝘀𝗲 𝗼𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗱𝗲𝘀𝗶𝗴𝗻. 𝗧𝗵𝗶𝘀 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗱𝗶𝘃𝗲𝘀 𝗶𝗻𝘁𝗼:   • A pharmacokinetic/pharmacodynamic model for the main organs of oligonucleotide accumulation and elimination   • The screening cascade applied for selection of the optimal ASO   • How to evaluate the pharmacokinetic characteristics of a LNA ASO Learn from our experts, Elisabetta De Filippo, Senior Research Scientist, and Annalisa Mercuri, Research Expert in this webinar. 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝘁𝗼 𝘄𝗮𝘁𝗰𝗵 𝗵𝗲𝗿𝗲-https://hubs.ly/Q03hgDqk0 #Oligonucleotide #LNAChemistry #ASO

We're thrilled to announce that our Evotec community here on LinkedIn has now reached 𝟭𝟬𝟬,𝟬𝟬𝟬 𝗳𝗼𝗹𝗹𝗼𝘄𝗲𝗿𝘀! Thank you for the insightful exchanges of information, engaging comments and all who have followed our journey this far. As we continue to share our passion towards medicines that matter, 𝘄𝗲 𝘄𝗼𝘂𝗹𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗸𝗻𝗼𝘄 𝘄𝗵𝗮𝘁 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝘀 𝘆𝗼𝘂. What would you like to see us post more about? Drop your thoughts in the comments below! And once again, 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗯𝗲𝗶𝗻𝗴 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆. Here's to the next 100,000!

We are heading to #AACR25! Join us as we present our 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗕𝗶𝗧𝗰𝗼 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, designed to enhance the efficacy of CD3 T cell engagers through CD2 costimulation 𝗣𝗼𝘀𝘁𝗲𝗿 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:   • Unique CD2 binder: A proprietary antibody directed against a unique epitope in CD2 and forms the basis of our novel BiTco format.   • Generation of Costimulatory CD2 Bispecifics: Introducing our proprietary CD2 BiTco platform, designed to drive CD2-mediated T cell costimulation in a tumor antigen-dependent manner   • Overcoming immune escape: BiTco costimulation achieves potent anti-tumor cytotoxicity even at low signal 1 conditions and when tumors lack CD58 expression   • in vivo Proof of Concept: Combination treatment with HER2×CD2 BiTco and EpCAM×CD3 TCE unlocks significant anti-tumor response in trastuzumab-resistant breast cancer models. Dont miss this opportunity to connect with our experts and explore new possibilities for collaborations, 𝗱𝗿𝗼𝗽 𝗯𝘆 𝗼𝘂𝗿 𝗯𝗼𝗼𝘁𝗵 #𝟮𝟱𝟰𝟮 or arrange a meeting here- https://hubs.ly/Q03hnfjS0

We are thrilled to announce our contributions to the agenda of next week's 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝗱 in Rome. Bernd Muehlenweg, SVP, Head of Global Business Development, Cell Therapy, will speak in the following two sessions: 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 Date and Time: Tuesday, 15 April at 5:00pm CET Location: Salone dei Cavalieri, Section 2 Showcase of Evotec's activities and advancements in the cell therapy space. 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗦𝗹𝗮𝗺 - Diabetes: Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions Date and Time: Wednesday, 16 April at 1:45pm CET Location: Salone dei Cavalieri, Section 3&4 Bernd is joined by Vlad Seitan, CSO Laverock Therapeutics, and Harald Stover, Ph.D., Founder and CEO, Allarta Life Science; Professor of Chemistry and Chemical Biology, McMaster University, to discuss novel approaches for diabetes treatment. The session will be moderated by Eytan Abraham, CCO and CTO, Minaris Regnerative Medicine 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝗿𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝗶𝗳 𝘆𝗼𝘂 𝘄𝗼𝘂𝗹𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗺𝗲𝗲𝘁 𝘂𝘀 𝗶𝗻 𝗥𝗼𝗺𝗲- https://hubs.ly/Q03g4crq0 #celltherapy #CGMed25 #iPSC

Michela Gabaldo, our VP, ATMP Global Regulatory Affairs is holding the key note lecture in today's digital event from AFI's (Associazione Farmaceutici Industria) on the evolution of regulation for advanced therapies. In her presentation, “From Bench to Bedside: navigating ATMP complex and evolving regulatory framework interplays”, Michela explains how the development of cell therapies could be optimized and accelerated through the navigation of the complex and multilayer regulatory landscape of these promising evolving field of therapeutics. She will further lay out the interplay of the different legislative frameworks and their relevancy for ATMP developers. Find out more about the event through AFI - ASSOCIAZIONE FARMACEUTICI INDUSTRIA and reach out to us if you are seeking regulatory solutions for your ATMP projects. info@evotec.com

Proud Moment for Evotec Italy! Evotec Named One of LinkedIn’s Top Companies in Italy 2025! We are thrilled to share that Evotec has been named one of LinkedIn’s Top Companies in Italy for 2025! This recognition highlights companies that empower their people, foster growth, and create meaningful opportunities for long-term success—and we couldn’t be prouder to see our commitment to people and innovation acknowledged on such a platform. A heartfelt thank you to all our colleagues in Verona and Modena — this achievement is yours. Your dedication, passion, and daily contributions make Evotec not just a great company, but a great place to grow and thrive. Read more on LinkedIn’s official ranking: https://hubs.ly/Q03gk-rK0 #LinkedInTopCompanies